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Systemic amyloidosis can be hereditary or acquired. The autosomal dominant, hereditary transthyretin 
amyloidosis and the acquired light-chain amyloidosis, the result of a plasma cell dyscrasia, are multi-system 
disorders with cardiovascular, autonomic and peripheral nerve involvement. There are numerous investigational 
modalities available to diagnose systemic amyloidosis and extent of organ involvement, but it is a frequently 
misdiagnosed condition due to heterogeneous clinical presentations, and misleading investigation findings. An 
accurate and timely diagnosis of amyloid neuropathy can greatly impact outcomes for patients, especially with 
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Abnormal ApoA1 + - + ++ ++ - - - Supportive, organ transplant 
ALys Hereditary Mutations in lysozyme gene 
Abnormal 
lysozyme - - +/- +++ ++ ++ - - Supportive, organ transplant 






dialysis b2M - (CTS) - +/- - +/- - - - Supportive, renal transplant 
Table 1: Summary of the common types of amyloid and most frequently affected organs1,2,3,17  
Abbreviations: b2M=b2-microglobulin-related. AFib= fibrinogen A a-chain. AGel= gelsolin amyloid. AL-amyloid= 
amyloid light chain. ALys= lysozyme amyloid. ASCT= autologous stem cell transplant. ATTR= amyloid transthyretin 
CTS- Carpal tunnel syndrome GIT= Gastrointestinal SAA= serum amyloid. AA= amyloid A. AApoA1= 
apolipoprotein A1 amyloid. +++ very common; ++ common; + less common, +/- rare; - does not occur or not 
applicable 
 
The hereditary amyloidoses, of which transthyretin (hATTR) is the most prevalent, are a rare group of autosomal 
dominant disorders characterised by varying severity of peripheral and/or autonomic neuropathy, and other 
systemic manifestations, particularly cardiomyopathy. Hereditary ATTR has been reported throughout the world, 
particularly in Europe, with marked phenotypic heterogeneity3. TTR is primarily synthesized in the liver and 
misfolding of the ATTR protein causes aggregation and formation of insoluble amyloid fibrils which deposit 
systemically4. Wild-type TTR is also a precursor of amyloid fibrils usually resulting in a late onset cardiomyopathy  
affecting approximately 25% of people over 80 years of age5. AL-amyloidosis is the result of a plasma cell 
dyscrasia in which monoclonal plasma cells produce immunoglobulin light chain fragments that abnormally fold 
and deposit6. AL-amyloidosis may be associated with myeloma or other B-cell malignancies, but most commonly 
the underlying haematological diagnosis is a benign monoclonal gammopathy of undetermined significance 
(MGUS). Lambda light chains are four times more commonly associated with AL-amyloidosis than kappa7.  
This review will focus on hATTR and AL-amyloidosis as they are most commonly associated with a neuropathy. 
Recognising amyloid neuropathy is very important in this era of imminently available genetic therapies for hATTR, 
and improving therapies with better survival rates for patients with AL-amyloidosis8. 
 
MAJOR CLINICAL FEATURES 
Hereditary ATTR and AL-amyloidosis have overlapping clinical manifestations and both may initially present with 
isolated carpal tunnel syndrome (CTS). Patients then generally develop a peripheral and autonomic neuropathy 
and frequently cardiac involvement. CTS can be the only symptom in hATTR in up to 33% of patients for a mean 
period of 4-6 years9 before other organs are clinically involved, and in AL-amyloidosis, it can predate other 
symptoms by over a year10. The most common hATTR mutation worldwide is the V30M mutation that is endemic 
in Portugal, Japan and Sweden but there are now more than 100 known pathogenic ATTR mutations. In Portugal, 
V30M classically presents in the second or third decade with a painful or uncomfortable peripheral neuropathy 
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with most patients describing paraesthesia or neuropathic pain initially rather than numbness progressing in a 
length-dependent pattern. Autonomic involvement can also be an initial symptom. In the UK, the majority of 
patients have the T60A point mutation, which originally arose in north-west Ireland at least 200 years ago, and 
is  widely prevalent in areas of high Irish immigration11. Classically, there is early cardiac involvement, which can 
be the presenting symptom usually around age 60. Symptoms and signs of peripheral neuropathy are the initial 
complaint in approximately 50% of patients, and are often characterised by numbness rather than a painful 
neuropathy12.  
As TTR is also produced within the choroid plexus and the epithelium of the retina, central nervous system (CNS) 
manifestations can also occasionally be seen in clinical practice, either from ongoing CNS deposition post liver 
transplant for V30M mutation or from hATTR mutations that have a predilection for the 
CNS. Oculoleptomeningeal amyloidosis, associated with the L12P mutation and other mutations can present with 
a variety of neurological problems including epilepsy, subarachnoid haemorrhage, hearing or visual loss and 
headaches13. hATTR-V30M patients have a 10-year survival rate from liver transplant of 75.4%, and focal 
neurological episodes are being reported a median of 11 years after transplant. These include ischaemic and 
haemorrhagic strokes, short-lived, stereotyped episodes suggestive of seizures, or cortical TIAs. They have been 
difficult to classify as most patients have normal EEGs and CT scans, and MRIs are often contraindicated due to 
a pacemaker or implantable cardioverter defibrillator. However, histopathological studies of post-transplant 




Neuropathic symptoms can be the presenting feature in up to 15% of patients with AL-amyloidosis10. In both AL-
amyloidosis and hATTR, patients typically describe a painful, length-dependent neuropathy starting in the feet, 
with numbness, burning, and allodynia, which can be particularly troublesome at night. However, this can vary 
in hATTR depending on the mutation such that patients with the V30M mutation from the endemic areas in 
Portugal present with this classic phenotype usually in the second or third decade whereas patients with the 
T60A Irish mutation present usually in the fifth or sixth decade and only 42%  have a painful neuropathy. 
Presentation of hATTR in non endemic areas, including patients with late onset V30M,  and many other mutations 
particularly if late onset,  can be much more variable  with a neuropathy characterised by the early involvement 
of all sensory fibers and in some cases more rapid progression15. In the classic presentation, examination at an 
early stage may show only features of small fibre involvement with abnormalities in pinprick sensation, and 
clinical features of median neuropathy at the wrists. Within months to years, large sensory fibres and motor 
nerve fibres become involved, resulting in impairment of vibration, proprioception and weakness starting distally 
but progressing proximally requiring walking aids and eventually wheelchair use, and impaired upper limb 
function2. Less commonly seen are focal cranial neuropathies, or plexopathies from focal deposition2. Isolated 
amyloid myopathy or myopathy associated with systemic amyloidosis, either genetic or acquired, is also 
recognised, and can occur with or without a neuropathy16,17. 
 
Autonomic Neuropathy 
Up to 75% of patients with hATTR, and 65% of patients with AL-amyloidosis develop symptoms of an autonomic 
neuropathy, affecting the cardiac, gastrointestinal, and genitourinary systems18,19. In our experience, diarrhoea 
and postural hypotension are among the most disabling symptoms of systemic amyloidosis. Orthostatic 
hypotension can be asymptomatic, or can cause persistent fatigue, light-headedness upon standing or syncope. 
Gastrointestinal manifestations include gastroparesis, weight loss from early satiety, and socially prohibitive, 
unexpected diarrhoea, which can be nocturnal, especially initially, and cause incontinence. Erectile dysfunction 
may be an early feature in men, and urinary frequency and retention can also occur. Pupillary and sweating 
abnormalities have been reported2. 
 
Extra-neurologic manifestations 
Amyloidosis can affect any organ or space, causing either dysfunction or organomegaly, for example 
hepatomegaly from AL-amyloid. Certain patterns of involvement are very suggestive of amyloidosis, such as 
macroglossia and bilateral periorbital bruising, (‘racoon eyes’) for AL-amyloidosis. Nephritic or nephrotic 
syndrome can occur with both genetic and acquired forms9. In addition, vitreous deposits occur in about 10% of 
patients with hATTR (never described with the Irish T60A mutation) and can sometimes be seen by direct 
ophthalmoscopy. Significant cachexia in both hATTR and AL-amyloid is frequently seen, with patients easily losing 
more than 10% of bodyweight.  
Symptoms of cardiac amyloidosis can present from either restrictive cardiomyopathy or arrhythmias. The 
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cardiomyopathy causes symptoms of heart failure, which can be difficult to manage, requiring careful 
consideration of the patient’s fluid status and hypotension from autonomic neuropathy. Symptoms of 
arrhythmias such as syncope, reduced exercise tolerance and fatigue can also be difficult to distinguish from 
symptoms of orthostatic hypotension. Typical findings on echocardiography include thickening of ventricular 
walls, however, cardiac magnetic resonance imaging (MRI) is more sensitive20. 
 
The diagnosis of amyloid is easier to recognise when patients present with a classic phenotype of symptomatic 
cardiomyopathy, previous bilateral CTS release and a progressive, length dependent, painful sensorimotor 
neuropathy (Figure 1). However, the neuropathy may be the only presenting feature and not be painful, and 
actively searching for other organ involvement can help strengthen the case for investigating for amyloidosis.  
 
APPROACH TO DIAGNOSIS 
 
Confirm neuropathy  
Patients are likely to present to a neurologist with symptoms suggestive of a peripheral neuropathy or be 
referred with a known diagnosis of amyloidosis to be investigated for a clinical or subclinical neuropathy. 
Standard nerve conduction studies (NCS) can be normal in early small fibre neuropathy (SFN). Testing for small 
fibre dysfunction is dependent on resources available locally. Quantitative sensory testing (QST) is often used in 
assessment for SFN and includes thermal detection and pain thresholds. The most validated technique to 
diagnose SFN is quantification of intra-epidermal nerve fibre density on a skin punch biopsy. In studies where 
SFN was clinically suspected, this assessment had a sensitivity of 90% and specificity of 95%21. With time the 
large fibres are involved and classically, NCS show a sensory more than motor, lower limb predominant axonal 
neuropathy with median nerve entrapment at the wrists22. However, in both hATTR and AL amyloidosis, slow 
conduction with prolonged distal motor latencies can be seen which may lead to a neurophysiological diagnosis 
of a demyelinating neuropathy and subsequently a clinical diagnosis of chronic inflammatory demyelinating 
polyneuropathy (CIDP).  Asymmetry can be seen in up to 50% of patients.  
 
Investigate cause of neuropathy 
Once a neuropathy is confirmed, the extent of investigations for the cause could be very minimal if there is a 
strong family history. Given the recent development of effective treatments for hATTR, we have a low threshold 
for requesting TTR gene sequencing in idiopathic axonal neuropathy or treatment resistant/atypical CIDP 
especially if accompanied by CTS, autonomic or cardiac involvement or the patient is of Irish ancestry. Testing is 
available on the NHS with results available within 4-6 weeks or sooner in an urgent situation. ATTR amyloidosis 
can be excluded if genetic testing for TTR is negative (no mutation), as sequence analysis of the gene detects 
more than 99% of pathogenic variants23. An online database 
(http://www.amyloidosismutations.com/main_menu.html) provides an updated list of amyloidogenic mutations 
and their phenotypes7. Wild-type ATTR remains a possibility as it cannot be excluded on genetic testing.  
If there is no family history, usually a broad, routine neuropathy screen will be conducted for acquired causes. 
When considering AL-amyloidosis, it is important to identify the monoclonal plasma cells through searching for 
a paraprotein as well as the culpable light chain causing the amyloidosis. In patients with AL-amyloidosis, the 
sensitivity of serum protein electrophoresis for detecting a monoclonal protein is 66% but increases to greater 
than 90% if one combines serum electrophoresis with immunofixation and Bence Jones protein testing on urine. 
Serum free light chain assay has a sensitivity of 88%24. Lambda is the causative amyloid light chain four times 
more often than kappa light chains7. The absolute values and the ratio need to be interpreted with caution in 
patients with renal impairment. Referral to a haematologist is necessary upon the identification of an abnormal 
light chain or paraprotein. 
 
Amyloidosis is a histologic diagnosis. Given its multi-system involvement, in cases of an appropriate neurologic 
phenotype, with no other obvious cause, and identification of a TTR mutation on genetic testing, or 
haematological findings suspicious for AL-amyloidosis, we do not necessarily pursue a nerve biopsy and 
sometimes use less invasive tissues to biopsy to achieve a diagnosis, such as an abdominal fat biopsy. However, 
in the absence of strongly supportive clinical findings, we do a nerve biopsy to search for amyloid and exclude 
other treatable causes. Identifying amyloid on sural nerve biopsies has a sensitivity cited as high as 86%, however, 
in real life, it can be challenging in an individual patient, given the patchy and sometimes proximal nature of 
amyloid deposition. It is not uncommon to only identify axonal degeneration in a nerve biopsy without identifying 
amyloid deposits, despite meticulous examination by the pathologist25.  
In the UK, once a diagnosis of amyloidosis is confirmed or strongly suspected, these patients are usually referred 
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to the National Amyloidosis Centre (NAC) for assessment of the extent of systemic involvement. Patients will 
usually undergo an abdominal fat aspiration, which is a simple and safe, bedside procedure if histological 
confirmation of amyloidosis has not been achieved previously. The specificity of this test in identifying systemic 
amyloidosis approaches 100% with sensitivity varying between 52% to 88%22. Congo red-positive areas of the 
formalin-fixed paraffin-embedded biopsy undergo immunohistochemistry for typing of the amyloid protein (TTR 
vs. AL vs. other), and if this is equivocal, the biopsy undergoes laser microdissection followed by mass 
spectrometry26. These tests to identify protein type can be performed on any affected tissue including salivary 
gland, nerve, rectal mucosa, endomyocardial biopsy specimens and tenosynovial tissues obtained at carpal 
tunnel release surgery.  
 
The NAC and other specialist centres also have specialised imaging modalities to identify the degree of systemic 
amyloidosis and the pattern of uptake can provide clues to type of amyloid. Serum amyloid P (SAP) is a 
glycoprotein found in all types of amyloid deposits. SAP scintigraphy uses radiolabelled SAP as a tracer to 
quantify and identify amyloid deposition, however, heart, peripheral nerve and the CNS are poorly visualised. 
SAP scintigraphy has high sensitivity, 90%, in AA and AL amyloidosis27, but only 48% in ATTR amyloidosis28 (Figure 
2). Another radionuclide tracer used is 99m-technetium-3,3,-diphosphono-1,2-propanodicarboxylic acid 
(99mTc-DPD). It is particularly sensitive and specific in identifying cardiac ATTR amyloid deposits, and ATTR 
deposits have different uptake and much higher sensitivity than AL-amyloid deposits27 (Figure 3).  
 
The coexistence of MGUS with wild-type or hATTR is recognised, especially in older people, but not widely 
appreciated. In a study of 57 patients with V122I mutation related hATTR, aged between 50-90, median age 71 
years, 49% had abnormal serum free light chain ratios and/or paraprotein on immunofixation29, suggesting 
neurologists may see abnormal haematological investigations commonly in these patients. Therefore, even in 
the presence of TTR-FAP mutations, AL-amyloidosis is possible and vice versa. Hence, biopsies from different 
sites and organs may be necessary and typing the amyloid fibrils is essential when there is concurrent ATTR 
mutation and a paraprotein.  
 
MISDIAGNOSES/ DIFFERENTIALS 
The most common misdiagnosis of amyloidosis is CIDP. This is plausible given patients with hATTR or AL-
amyloidosis can have significant motor conduction velocity slowing. In one study, seven misdiagnosed patients 
fulfilled EFNS/PNS criteria for definite demyelinating polyneuropathy (See clinical case 1). Reduced conduction 
velocities as low as 33 m/s in the upper limbs and 30 m/s in the lower limbs were observed30. In a study of 150 
patients with hATTR, 32% had been misdiagnosed, 61% of these were initially diagnosed as CIDP, and 2% as 
vasculitic neuropathy, which can also present as a painful, axonal neuropathy30. Contributing to the risk of 
misdiagnosis is raised CSF protein in patients with systemic amyloidosis and the clues of autonomic and systemic 
involvement being absent at initial presentation. Given the frequent misdiagnosis, there should be high 
suspicion for hATTR in patients diagnosed with CIDP that do not respond to immunomodulatory treatment31 
(Other pitfalls are listed in Table 2).  
 
Table 2: Pitfalls in diagnosing amyloid neuropathy  
PITFALLS IN DIAGNOSING AMYLOID NEUROPATHY 
History 
No family history 
Minimal pain at onset 
Paraesthesia rather than pain 
Asymmetric 
No cardiac or autonomic symptoms 
Examination 
Cranial nerve involvement  
Proximal weakness early 
Investigations 
Concurrent paraprotein with hATTR 
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Raised CSF protein 
Slow conduction velocities on NCS  
Myopathic units on EMG 
Failure to identify amyloid on first tissue biopsy- may need 




For AL-amyloidosis, high dose melphalan and autologous stem cell transplantation (HDM-ASCT) is the preferred 
ﬁrst-line treatment for patients up to 65–70 years of age and eligibility depends on the extent of renal, cardiac, 
autonomic and bone marrow involvement. HDM-ASCT, in a carefully selected patient population, is associated 
with the best progression free survival and overall survival, with treatment related mortality of 4-13%32. Patients 
not eligible for HDM-ASCT generally receive systemic chemotherapy with melphalan and dexamethasone or 
cyclophosphamide-bortezomib-dexamethasone (VCD)33. Prognosis depends on the extent of cardiac 
involvement (monitored through serum biomarkers) and the difference in quantities (rather than ratio) between 
involved (amyloidogenic light chain) and uninvolved serum free light chain levels.  
It is an exciting time for patients and clinicians in the field of hATTR. Historically, liver transplant was the first 
treatment option for hATTR, first performed in 1990 and while it increases survival in early onset ATTR-V30M 
(patients less than 50 years old), outcomes in non-V30M and older V30M patients are not as good. In recent 
times, TTR stabilisers, Tafamidis and diflunisal have been used to treat patients with hATTR. These drugs bind to 
thyroxine-binding sites of TTR and inhibit TTR tetramer dissociation (an essential step for amyloid formation) 
and there is some evidence that they may slow disease progression, especially in the V30M patient population34. 
This year, there has been significant progress made in treatment for hATTR with two types of gene silencing 
therapies, inotersen, an antisense oligonucleotides (ASOs) and patisiran, a small interfering RNAs (siRNAs), 
achieving their primary outcome measures in two separate randomised placebo-controlled, phase 3 trials 35,36. 
Inotersen is a subcutaneous preparation and is administered weekly, while patisiran is administered 
intravenously, three-weekly. They both reduce the production of mutant and wild-type TTR through different 
mechanisms (for further information on mechanisms, please read 8). These therapies are a welcome addition to 
the treatment options for patients with V30M and non-V30M mutations.  
 
Conclusion 
In this era of rapidly evolving gene therapies for hATTR and improving therapies for AL-amyloidosis, an accurate 
and timely diagnosis of amyloid neuropathy can greatly impact outcomes for patients. There is considerable 
heterogeneity in the clinical presentation of amyloid neuropathy but having a high clinical suspicion together 




Case 1 (TTR misdiagnosed as CIDP): 
A 70-year-old lady, of Northern Irish background, was initially diagnosed as having CIDP based on asymmetrical, 
distal, sensory-onset neuropathy, raised CSF protein of 0.69 g/L and prolonged distal motor latencies and slowed 
conduction velocities on neurophysiology. She was referred to our centre after failing to respond to 
prednisolone, intravenous immunoglobulin and plasma exchange. At age 66, she developed unilateral, 
uncomfortable paraesthesia in her left foot, which over a year spread to both knees. Following this she 
developed proximal weakness with trouble standing up from sitting which progressed such that she required a 
wheelchair 3 years after disease onset. There was no weight loss, early satiety, bowel or bladder symptoms but 
she did have postural dizziness, which developed two years in to her illness. Her other history included atrial 
fibrillation (AF), diagnosed at age of 68. There was no family history of neurological disease.  
On examination, four years after the onset of her illness, she had upper limb weakness of MRC 4 proximally and 
0-1 distally. Lower limb examination revealed pitting oedema to her ankles, global weakness with proximal 
power of MRC 2-3, and distal power of 0-2.  She was areflexic and had downgoing plantars. Sensory examination 
revealed reduced pinprick to her knees and elbows, normal joint position sense, and reduced vibration to ankles.  
Neurophysiology showed a mixed, demyelinating and axonal neuropathy (Table 3).  
 
Table 3: Case 1 Neurophysiology  
Sensory Nerve Conduction Studies   
Right  Left 
Median (D3- wrist) Absent  Absent  
Ulnar (D5- wrist) Absent  Absent  
Sural (calf- ankle) Absent  Absent  
Sup. peroneal (calf- ankle) Absent  Absent  
Motor Nerve Conduction Studies 
Median (SE on APB) 
  
DML (wrist) 13 ms 7.0 ms 
CV(wrist-elbow) 47 m/s 35 m/s 
CMAP(wrist) 2.5 mV 1.2 mV 
CMAP(elbow) 1.7 mV 0.9 mV 
Ulnar (SE on ADM)     
DML 4.6 ms 3.6 ms 
CV(wrist-below elbow) 47 m/s 44 m/s 
CV(around elbow) 42 m/s 45 m/s 
CV(above elbow-axilla) 43 m/s 45 m/s 
CMAP(wrist) 2.5 mV 4.0 mV 
CMAP(below elbow) 1.7 mV 3.5 mV 
CMAP(above elbow) 1.7 mV 2.9 mV 
CMAP(axilla) 1.5 mV - 
Minimal F-wave latency (wrist) absent - 
Common Peroneal (SE on EDB)     
CMAP(ankle) absent - 
Tibial (SE on AH)     
CMAP(ankle) absent - 
 
Cerebrospinal fluid analysis showed a raised protein of 0.69 g/L. Sural nerve biopsy identified endoneurial 
deposits that stained strongly with Congo Red and displayed apple-green birefringence when viewed under 
polarized light (Figure 4). Immunotyping was suggestive of transthyretin type of amyloid. Sequencing of the TTR 
gene revealed the T60A pathogenic mutation. DPD scan at the NAC showed moderate amount of cardiac 
amyloid. She was treated with diflusinal, a TTR stabiliser.  
 
Case 2 (AL difficult to diagnose on tissue):  
A 70-year-old lady with a six-year history of Waldenstrom’s macroglobulinemia, previously treated with 
fludarabine and cyclophosphamide, with partial haematological response secondary to early cessation of 
treatment due to side effects, presented with a year history of shooting pains in the calves and burning in the 
soles of the feet. Three months prior to referral to our centre, she developed weakness in her feet and difficulty 
climbing stairs progressing to using a wheelchair after a further three months. 
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On initial examination, there was no postural hypotension. Cranial nerve examination was normal except for a 
left tonic pupil. In her upper limbs, there was bilateral wasting of the intrinsic hand muscles. Power was normal 
proximally and MRC 4 to 5 in the intrinsic hand muscles. Reflexes were present. In the lower limbs, she could 
not stand from a chair without using her hands and had bilateral wasting of EDB. Tone was normal and there 
was proximal and distal weakness, with hip flexors weak at MRC 4, and ankle dorsiflexion was 4 on the right and 
2 on the left. Knee reflexes were present, ankle jerks were absent, and plantars were unresponsive. Sensory 
examination showed pinprick abnormal to mid-thighs with no abnormality in the upper limbs, vibration was 
reduced to the costal margins and proprioception was normal.  
Initial investigations showed an IgM lambda paraprotein of 5.1g/L, normal serum free light chains with a normal 
ratio and no urine Bence Jones protein. Neurophysiology revealed abnormal thermal thresholds in the lower 
limbs suggesting a small fibre neuropathy with no large fibre involvement. Repeat neurophysiology six months 
later showed an axonal, asymmetric neuropathy (Table 4).  
 
Table 4: Case 2 Neurophysiology 
Sensory Nerve Conduction Studies   
Right Left 
Radial (forearm-snuffbox) 37µV 69m/s - - 
Median (D3- wrist) 12µV 60m/s - - 
Ulnar (D5- wrist) 9µV 57m/s - - 
Sural (calf- ankle) 5µV 60m/s 4µV 55m/s 
Sup. peroneal (calf- ankle) absent - absent - 
Motor Nerve Conduction Studies  
Right Left 
Median (SE on APB)     
DML (wrist) 3.2 ms - 
CV (wrist-elbow) 50 m/s - 
CMAP (wrist) 5.5 - 
CMAP (elbow) 4.7 - 
Minimal F-wave latency 28.2 ms - 
Ulnar (SE on ADM)     
DML 2.6 ms - 
CV (wrist-below elbow) 58 m/s - 
CMAP (wrist) 8.0 mV - 
CMAP (below elbow) 6.1 mV - 
CMAP (above elbow) 7.4 mV - 
Minimal F-wave latency  27.3 ms - 
Common Peroneal (SE on EDB)     
DML 4.7 ms 4.9 ms 
CMAP (ankle) 1.2 mV 0.2 mV 
CMAP (fib neck) 1.0 mV 0.2 mV 
F latency 56.1 ms   
Tibial (SE on AH)     
DML 5.5 ms 5.9 ms 
CMAP (ankle) 1.4 mV 2.1 mV 
Minimal F-wave latency 65.0 ms 51.8 ms 
 
She underwent a superficial peroneal and peroneus brevis biopsy which showed a moderate loss of large 
myelinated fibres and moderate loss of all axons. Immunohistochemical studies showed endoneurial labelling 
for lambda light chains, however, Congo red staining at our institution was negative. The biopsy was sent to NAC 
for further studies, and using antibodies against SAP, they were able to show amyloid deposits present in the 
nerve bundles. Antibodies against SAP, which co-deposits with amyloid, can be used to distinguish light chain 
deposits of AL amyloidosis from monoclonal immunoglobulin deposition disease (19). Assessment at the NAC 
revealed nephritic range proteinuria and SAP scintigraphy showed moderate splenic amyloid load as well as 
equivocal liver involvement, with no evidence of cardiac amyloidosis. 
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Her mobility continued to deteriorate and she developed features of autonomic neuropathy with urinary 
retention, diarrhoea and orthostatic hypotension. She was treated with cyclophosphamide, dexamethasone and 




Box 2: Key Messages  
 
• Systemic amyloidosis can be hereditary or acquired with hereditary transthyretin (TTR) amyloidosis 
being the most common inherited form.  
• Systemic amyloidosis is a multi-system disorder with varying involvement of the peripheral and 
autonomic nerves, and particularly, cardiac involvement.  
• The classic neuropathic presentation is of a painful, length dependent neuropathy but atypical 
presentations without pain or presentations of focal neuropathies, plexopathies or myopathy, are not 
uncommon. 
• Classically, neurophysiology suggests an axonal neuropathy, but standard nerve conduction studies can 
be normal in early small-fibre neuropathy, and slow conduction velocities or prolonged distal motor 
latencies can also be seen leading to a clinical misdiagnosis of CIDP. 
• Older patient may have concurrent hereditary TTR amyloidosis and a paraprotein which can complicate 
identifying AL vs. TTR amyloidosis.  
• Consider requesting TTR gene sequencing in patients diagnosed with CIDP who do not respond to 
immunomodulatory treatment.  
• There is exciting progress being made in treating hereditary TTR amyloidosis with 2 gene-silencing 
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